CGMP Consulting Fees: Section 37 Deduction and TDS Under 194J and 195

An Indian listed pharma group at the scale of Dr Reddy’s Laboratories receives a USFDA Form 483 at the close of a pre-approval inspection at its Bachupally formulations campus in Telangana on 18 November 2025. The 483 lists observations across data-integrity gaps in the HPLC laboratory, method-validation lapses on a Category 1 complex-generic pipeline, and CAPA closure delays across the previous 18 months. The group’s audit committee approves a FY 2026-27 remediation programme with a costed CGMP consulting envelope of approximately Rs 7.65 crore — Rs 4.2 crore to a US-parent CGMP consulting firm at the scale of Lachman Consultant Services or Parexel Consulting for gap assessment and remediation methodology, Rs 2.8 crore to that firm’s India-subsidiary for on-site programme management and validation execution, and Rs 65 lakh to an Indian sub-contractor data-integrity audit lab. Every invoice against this envelope must simultaneously satisfy the Section 37 wholly-and-exclusively test for revex deductibility, the correct TDS classification at source, the DTAA rate on the foreign consultant leg, and the Form 15CA/15CB filing before the AD Bank remittance. This is CGMP consulting fees Section 37 deduction Section 194J 195 pharma at operating scale, and the discipline that keeps the tax audit under Form 3CD Clause 21 clean, the Section 195 remittance chain matched to the India-USA DTAA Article 12 rate on Fees for Included Services, and the Ind AS 37 provision utilisation tied to the aggregate Section 37 claim is what separates a remediation programme that lands on plan from one that spends the following fiscal year litigating a mis-characterised consulting invoice at assessment.

Quick reference

The reconciliation in one paragraph

A CGMP remediation consulting fee register on a large post-Form 483 programme runs a four-sub-register reconciliation cascade that must close together at every quarter. Sub-register one is the Section 37 wholly-and-exclusively test evidence file — each invoice carries a narrative link to the specific 483 observation being addressed, a work-order reference, and a business-restoration argument. Sub-register two is the Section 194J code 1005 TDS register on Indian consultants — payee PAN, invoice amount, TDS deducted at 10 percent, TRACES challan reference, and Form 26AS mapping. Sub-register three is the Section 195 remittance register on foreign consultants — payee tax residency, DTAA rate applied (15 percent under India-USA Article 12 for US consultants after the make-available test), TRC and Form 10F on file with expiry date, Form 15CA Part C and Form 15CB filing reference, AD Bank remittance reference, and challan match. Sub-register four is the DTAA TRC evidence file — the physical TRC issued by the US IRS (or equivalent tax authority for consultants from other jurisdictions), the Form 10F declaration, and the accountant’s certificate in Form 15CB, with expiry dates tracked so a lapsed TRC does not cause a silent fall-back to the domestic rate on the next remittance. All four sub-registers cross-tie to the aggregate Section 37 claim in the tax return and to the ledger control total for the year.

What the scenario looks like in India — safe illustrative brand persona

The USFDA CGMP consulting market in India converges on a small set of specialist firms that Indian pharma groups engage repeatedly across the observation-to-close-out cycle. On the US-parent side the mainstream engagements are with Lachman Consultant Services (a Long Island, NY specialist firm with a long track record on FDA remediation for API and finished-dosage manufacturers), Parexel Consulting (a division of the clinical-CRO group with a dedicated CGMP compliance practice), PQE Group (an Italian-origin global CGMP and validation consultancy with US practice), NNE (Novo Nordisk Engineering — Danish-origin, biopharma-focused), and KVK-Tech and a handful of other US-based independents. On the India-subsidiary side the same firms typically operate through a wholly-owned Indian subsidiary or affiliate that carries out the on-site programme management, validation execution, and documentation upgrade work. On the Indian-independent side there is a broader pool of validation specialists, data-integrity audit labs, calibration houses, and quality-systems consultants who are engaged as sub-contractors on specific work streams.

The illustrative persona for this article is a Category 1 integrated formulator at the scale of Dr Reddy’s Laboratories, with its Bachupally formulations campus in Telangana receiving a Form 483 in November 2025 covering data-integrity, method-validation, and CAPA-closure observations. The persona applies equally to any of Sun Pharmaceutical Industries (Halol, Dadra, Karkhadi historical inspections), Aurobindo Pharma (multiple US-market injectable plants), Cipla (Goa, Kurkumbh), Lupin (Somerset NJ, Coral Springs), Glenmark (Halol, Baddi, Monroe NJ), Zydus Lifesciences (Moraiya, Ahmedabad), Torrent (Indrad), Piramal Pharma (Digwal), Divi’s Labs (Vishakhapatnam, Kakinada), Alkem Laboratories, and Cadila Pharmaceuticals across the TIER 1 formulator pool, and to Biocon Biologics (Bommasandra), Ipca Labs, Ajanta Pharma, Suven Pharma, Neuland Labs, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, and JB Chemicals across the TIER 2 speciality houses. The regional pharma manufacturing geography that anchors the persona — Bachupally, Bollaram, Hyderabad, Vishakhapatnam, Ankleshwar, Vadodara, Ahmedabad, Halol, Baddi, Kurkumbh, Verna, Aurangabad — covers the plants that generate the bulk of the Form 483 flow to USFDA-registered facilities in India.

The regulatory overlay — Section 37, Section 194J code 1005, Section 195, India-USA DTAA Article 12

Four regulatory anchors govern the CGMP consulting fee register on a USFDA remediation programme, and each maps to a specific reconciliation surface. The overarching frame is set out in the USFDA Form 483 remediation cost accounting guide cornerstone; this depth article isolates the consulting-fee slice and drills into the TDS and DTAA mechanics.

Section 37(1) of the Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) is the residuary revex deduction provision. It allows deduction of any expenditure not covered by Sections 30 to 36, not being capital expenditure or personal expense, laid out wholly and exclusively for the purposes of the business or profession. A CGMP consulting fee paid to a US-parent firm or an India-subsidiary firm to close observations on a Form 483 and to restore export access to the US market is expenditure wholly and exclusively for the purposes of the pharma group’s business. Explanation 1 to Section 37 bars deduction where expenditure is incurred for a purpose which is an offence or which is prohibited by law — CGMP consulting to restore compliance is the opposite of an offence, and the bar does not apply. Any civil penalty or consent decree fine paid separately to a US regulator would be disallowed under Explanation 1 because the payment itself is punitive, but that is a distinct category from the consulting fee. The wholly-and-exclusively test evidence — a narrative link from invoice to specific 483 observation, a work-order reference, and a business-restoration argument — must be documented per invoice in the Form 3CD Clause 21 tax-audit pack.

Section 194J read with payment code 1005 governs TDS on fees for professional or technical services rendered by an Indian resident. The rate is 10 percent for professional services above the aggregate annual threshold of Rs 30,000 per payee per category. An India-subsidiary CGMP consulting firm (the local subsidiary or affiliate of the same global consulting group whose US-parent is the primary engagement counterparty) and an Indian sub-contractor data-integrity audit lab are both deducted at 10 percent under code 1005. The TDS is remitted to TRACES against the payee’s PAN and reported on the payee’s Form 26AS. Where the payee’s aggregate credit or payment in the financial year is below Rs 30,000, no deduction is required — but on a large remediation programme the aggregate crosses the threshold within the first invoice, and the pharma group typically deducts from rupee-one to avoid any inadvertent short-deduction exposure under Section 201.

Section 195 governs TDS on any sum chargeable to tax under the Act paid to a non-resident. The default domestic rate for Fees for Technical Services or Fees for Included Services (FIS) is 20 percent (plus surcharge and cess), and where the non-resident is treated as a foreign company without treaty relief the general 40 percent slab can apply. Section 90 gives the payer access to the lower of the domestic rate or the applicable DTAA rate, subject to the non-resident furnishing a Tax Residency Certificate under Section 90(4) and Form 10F under Section 90(5). For a US-resident CGMP consulting firm the India-USA DTAA Article 12 caps the Indian tax on Fees for Included Services at 15 percent of the gross amount, subject to the make-available test. The make-available test — that the services must make available technical knowledge, experience, skill, know-how, or processes to the payer — is satisfied where the US consultant delivers a CGMP gap-assessment report, a remediation methodology, and process templates that the Indian pharma group can subsequently apply on its own. Absent the TRC and Form 10F, the payer must deduct at the domestic rate; a lapsed TRC on the payee’s file causes a silent fall-back to the domestic rate on the next remittance, and the reconciliation surface must catch it. Form 15CA Part C and Form 15CB (accountant’s certificate) are filed on the CBDT e-filing portal before the AD Bank release under Rule 37BB, and the filing references are stored in the DTAA TRC evidence file. This TDS-on-non-resident-payments mechanic is elaborated in the TDS Section 195 non-resident payments guide.

Rule 44BB deserves explicit mention because it is sometimes mistakenly cited in cross-border services contexts. Rule 44BB (read with Section 44BB) prescribes a presumptive-taxation regime for non-residents providing services or facilities in connection with, or supplying plant and machinery on hire used or to be used in, the prospecting for or extraction or production of mineral oils. It is scoped to the petroleum industry — oil-and-gas exploration, drilling, seismic surveys, and directly-connected consultancy — and does not extend to pharmaceutical CGMP consulting. A US-parent CGMP consulting firm engaged for a post-Form 483 remediation programme falls under the general FIS regime through Section 195 read with the India-USA DTAA Article 12, not under Rule 44BB. Any attempt to apply the Rule 44BB presumptive rate to pharma CGMP consulting is a mis-characterisation that fails an assessment challenge, and the year-end tax audit working paper should record the non-application affirmatively.

A worked example — Dr Reddy’s Bachupally FY 2026-27 CGMP consulting engagement

Illustrative — the following figures represent the operating pattern of a Category 1 integrated formulator running a post-Form 483 CGMP remediation programme with a mixed US-parent and India-subsidiary consulting engagement. Public disclosures do not reveal per-invoice consultant fee splits or DTAA rate elections; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s tax position.

A Category 1 integrated formulator receives a Form 483 at its Bachupally formulations campus on 18 November 2025. The audit committee approves a FY 2026-27 CGMP consulting envelope of Rs 7.65 crore split across three counterparties.

Counterparty 1: US-parent CGMP consulting firm (Lachman-scale). Engagement fee Rs 4.20 crore for gap assessment, remediation methodology design, senior CGMP expert deputation, and USFDA response review across four visits during FY 2026-27. Deliverables include a gap-assessment report, a remediation methodology playbook, process templates, and training materials — the make-available test is satisfied. The firm furnishes a Tax Residency Certificate issued by the US IRS and Form 10F. The India-USA DTAA Article 12 rate of 15 percent applies. Section 195 TDS deducted = Rs 63 lakh. Form 15CA Part C and Form 15CB are filed on the CBDT portal before each remittance; the AD Bank releases the net remittance of Rs 3.57 crore aggregated across four tranches during FY 2026-27. Absent the TRC and Form 10F the domestic 40 percent slab would apply — TDS would be Rs 1.68 crore instead of Rs 63 lakh — a Rs 1.05 crore working-capital hit that the TRC discipline avoids.

Counterparty 2: India-subsidiary CGMP consulting firm. Engagement fee Rs 2.80 crore for on-site programme management, validation execution, documentation upgrade, and 12-month rolling engagement across the FY 2026-27 remediation window. Section 194J code 1005 at 10 percent applies. TDS deducted = Rs 28 lakh. TRACES challan is filed monthly and appears on the India-subsidiary’s Form 26AS.

Counterparty 3: Indian sub-contractor data-integrity audit lab. Engagement fee Rs 65 lakh for a five-week data-integrity audit of the HPLC laboratory, chromatography peak-integration review, and audit-trail reconstruction across 24 months of prior batch records. Section 194J code 1005 at 10 percent applies. TDS deducted = Rs 6.5 lakh. TRACES challan is filed on the invoice-payment date.

All three counterparty engagements are Section 37 revex — the consulting fee does not create a distinct capitalisable asset under Ind AS 16 and does not attract the capex tag. The aggregate Section 37 claim of Rs 7.65 crore in the tax return cross-ties to the Ind AS 37 remediation provision utilisation for the CGMP consulting work-order category and to the ledger control total for FY 2026-27. Any Section 40(a)(i) exposure on Counterparty 1 (non-resident) or Section 40(a)(ia) exposure on Counterparties 2 and 3 (residents) is closed by the timely TDS deduction and TRACES/CBDT filing. Terra Insight’s reconciliation playbook monthly close framework treats the consultant-wise invoice register as a specific month-end control point that must be signed off before the finance team closes the period.

Common reconciliation breakages

Five breakages recur across CGMP consulting fee registers on large remediation programmes, and each maps to a specific control failure.

• Lapsed TRC causes silent fall-back to domestic rate on the next remittance. A US-parent CGMP consulting firm furnishes a Tax Residency Certificate valid for the US calendar year (typically issued as Form 6166 for a specific tax year). Where the TRC expires between remittance tranches and the payer does not obtain a refreshed TRC before the next remittance, the payer is not entitled to the DTAA rate and must deduct at the domestic rate (20 percent for FTS/FIS or up to 40 percent for a foreign company without treaty relief). The reconciliation surface is a TRC expiry-date register with a 60-day pre-expiry alert to the counterparty and to the tax team. This lapsed-document class of error is treated as a specific detection surface in Terra Insight’s Detection Envelope framework and the reconciliation error catalogue — it is a Family 3 evidence-lifecycle failure where the underlying transaction is correct but the supporting evidence has aged out.

• Make-available test not documented per invoice, DTAA rate challenged at assessment. The India-USA DTAA Article 12 rate of 15 percent on Fees for Included Services applies only where the services make available technical knowledge, experience, skill, know-how, or processes to the payer. Where the invoice narrative is generic (“professional services for the period Nov-2025 to Feb-2026”) and there is no linked deliverable evidencing the make-available character, an assessment can re-characterise the fee as business profits under Article 7 (taxable only if the non-resident has a Permanent Establishment in India) or as generic services outside Article 12. Reconciliation discipline requires that each non-resident consulting invoice is accompanied by a deliverable list (gap-assessment report, remediation methodology playbook, process templates, training materials) that evidences the make-available character in the assessment record.

• Rule 44BB mis-characterisation attempt for pharma CGMP consulting. Rule 44BB and Section 44BB are scoped to petroleum-industry mineral-oil exploration and directly-connected consultancy. An occasional attempt to apply the Rule 44BB presumptive rate (10 percent of gross receipts deemed as profits) to a pharma CGMP consulting engagement is a mis-characterisation that fails an assessment challenge. The year-end tax audit working paper must record the non-application of Rule 44BB affirmatively and cite the applicability of the general FIS regime through Section 195 read with the India-USA DTAA Article 12 for the US-parent leg.

• Section 194J code 1005 threshold miss on an Indian sub-contractor. The Rs 30,000 annual threshold applies per payee per category. Where an Indian sub-contractor is engaged for a small first invoice under the threshold and the second invoice takes the aggregate above Rs 30,000, TDS must be deducted on the aggregate (not just the second invoice). Where the pharma group deducts only on the second invoice and not on the first, the short deduction on the first-invoice slice attracts Section 201 interest at 1 percent per month. Reconciliation discipline requires that the Section 194J register runs a rolling year-to-date aggregate per payee and that TDS is deducted from rupee-one where the payee is on a live engagement expected to cross the threshold.

• Form 15CA/15CB not filed before AD Bank remittance. Rule 37BB requires Form 15CA (self-declaration) plus Form 15CB (accountant’s certificate) to be filed on the CBDT e-filing portal before the remittance to the non-resident. Where the AD Bank releases the remittance without the Form 15CA/15CB filing being complete, the remittance is a violation of Rule 37BB and the pharma group is exposed to penalty under Section 271-I (Rs 1 lakh per default) in addition to the Section 40(a)(i) disallowance risk on the underlying invoice if the TDS chain is broken. Reconciliation discipline requires that the AD Bank release only follows the CBDT portal filing acknowledgement, and the filing reference numbers are stored in the DTAA TRC evidence file against the invoice.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the consultant master (vendor code, residency, TRC and Form 10F on file with expiry date, service category, payment terms), the Form 483 observation register with sub-work-order breakdown, the invoice batch from the ERP AP module, and the TRACES and CBDT filing acknowledgements — and produces a consultant-wise invoice register that closes four sub-registers in one view. The platform applies the correct TDS section and rate at source (Section 194J code 1005 at 10 percent for Indian residents above the Rs 30,000 threshold; Section 195 at the DTAA rate for non-residents with TRC + Form 10F on file; Section 195 at the domestic fall-back rate where TRC or Form 10F is absent or expired), pre-emptively alerts on TRC expiry 60 days before the next remittance, stores the Section 37 wholly-and-exclusively test evidence pack per invoice with the observation link, files the Form 15CA/15CB pair against each non-resident remittance and stores the CBDT portal acknowledgement, and cross-ties the aggregate CGMP consulting cost claimed under Section 37 in the tax return to the Ind AS 37 provision utilisation and to the ledger control total for the year. Match rate improvement of 51 to 88 percent on the CGMP consulting invoice register and the TRACES/CBDT filing reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Category 1 major formulator running a multi-year remediation programme rather than a spreadsheet substitute. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions pharma controllers and USFDA remediation programme managers ask most often when running the CGMP consulting fee register against the Form 3CD tax-audit pack.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024